AbbVie agrees to buy Apogee Therapeutics for $10.9 billion in cash to boost its anti-inflammatory drug pipeline amid competition for its top-selling drug.
bloomberg-industries06/22, 06:11 PM
Related assets
Coming up for ABBV
Explore next
Latest ABBV news
FirstSquawk08/20, 09:57 AM
Piper Sandler raised its price target on AbbVie to $303 from $298.
Bloomberg08/17, 06:28 PM
Bloomberg08/03, 04:58 PM